mScarlet/LUC Reporter Cell Line - HT29

The HT-29 cell line is a highly characterized and extensively utilized human model of colorectal adenocarcinoma, originally isolated from a primary colon tumor. It is a cornerstone in gastrointestinal oncology research, highly valued for its ability to faithfully replicate the complex biology of human colorectal cancer, including critical, clinically relevant genetic alterations such as the BRAF V600E and TP53 mutations. The mScarlet/Luc Reporter Cell Line - HT29 is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial morphology, the distinct molecular profile, or the intrinsic tumorigenic capacity of the original parental HT-29 cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the HT-29 model for comprehensive translational colorectal cancer research. For in vitro studies, the distinct mScarlet expression provides intense red fluorescence, allowing researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust luciferase activity serves as the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and metastatic dissemination through bioluminescence imaging (BLI). Because it is a human-derived cell line, the HT29-mScarlet/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly reliable subcutaneous xenografts, clinically relevant orthotopic colonic models, or robust models of hepatic metastasis. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds (such as BRAF or MEK inhibitors), and emerging biotherapeutics, facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects.